Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has also shown neuroprotective effects in experimental stroke models. However, while the neuroprotective efficacy of Exendin-4 has been thoroughly investigated if the pharmacological treatment starts before stroke, the therapeutic potential of the Exendin-4 if the treatment starts acutely after stroke has not been clearly determined. Further, a comparison of the neuroprotective efficacy in normal and aged diabetic mice has not been performed. Finally, the cellular mechanisms behind the efficacy of Exendin-4 have been only partially studied. The main objective of this study was to determine the neuroprotective efficacy of Exendin-4 in normal and aged type 2 diabetic mice if the treatment started after stroke in a clinically relevant setting. Furthermore we characterized the Exendin-4 effects on stroke-induced neuroinflammation. Two-month-old healthy and 14-month-old type 2 diabetic/obese mice were subjected to middle cerebral artery occlusion. 5 or 50 µg/kg Exendin-4 was administered intraperitoneally at 1.5, 3 or 4.5 hours thereafter. The treatment was continued (0.2 µg/kg/day) for 1 week. The neuroprotective efficacy was assessed by stroke volume measurement and stereological counting of NeuN-positive neurons. Neuroinflammation was determined by gene expression analysis of M1/M2 microglia subtypes and pro-inflammatory cytokines. We show neuroprotective efficacy of 50 µg/kg Exendin-4 at 1.5 and 3 hours after stroke in both young healthy and aged diabetic/obese mice. The 5 µg/kg dose was neuroprotective at 1.5 hour only. Proinflammatory markers and M1 phenotype were not impacted by Exendin-4 treatment while M2 markers were significantly up regulated. Our results support the use of Exendin-4 to reduce stroke-damage in the prehospital/early hospitalization setting irrespectively of age/diabetes. The results indicate the polarization of microglia/macrophages towards the M2 reparative phenotype as a potential mechanism of neuroprotection.

The toxic metalloid arsenic causes widespread misfolding and aggregation of cellular proteins. How these protein aggregates are formed in vivo, the mechanisms by which they affect cells, and how cells prevent their accumulation is not fully understood. To find components involved in these processes, we performed a genome-wide imaging screen and identified yeast deletion mutants with either enhanced or reduced protein aggregation levels during arsenite exposure. We show that many of the identified factors are crucial to safeguard protein homeostasis (proteostasis) and to protect cells against arsenite toxicity. The hits were enriched for various functions including protein biosynthesis and transcription, and dedicated follow-up experiments highlight the importance of accurate transcriptional and translational control for mitigating protein aggregation and toxicity during arsenite stress. Some of the hits are associated with pathological conditions, suggesting that arsenite-induced protein aggregation may affect disease processes. The broad network of cellular systems that impinge on proteostasis during arsenic stress identified in this current study provides a valuable resource and a framework for further elucidation of the mechanistic details of metalloid toxicity and pathogenesis.

No abstract

Inflammation plays a central role in neonatal brain injury. During brain inflammation the resident macrophages of the brain, the microglia cells, are rapidly activated. In the periphery, α7 nicotinic acetylcholine receptors (α7R) present on macrophages can regulate inflammation by suppressing cytokine release. In the current study we investigated α7R expression in neonatal mice after hypoxia-ischemia (HI). We further examined possible anti-inflammatory role of α7R stimulation in vitro and microglia polarization after α7R agonist treatment. Real-time PCR analysis showed a 33% reduction in α7R expression 72 h after HI. Stimulation of primary microglial cells with LPS in combination with increasing doses of the selective α7R agonist AR-R 17779 significantly attenuated TNFα release and increased α7R transcript in microglial cells. Gene expression of M1 markers CD86 and iNOS, as well as M2 marker CD206 was not influenced by LPS and/or α7R agonist treatment. Further, Mox markers heme oxygenase (Hmox1) and sulforedoxin-1 (Srx1) were significantly increased, suggesting a polarization towards the Mox phenotype after α7R stimulation. Thus, our data suggest a role for the α7R also in the neonatal brain and support the anti-inflammatory role of α7R in microglia, suggesting that α7R stimulation could enhance the polarization towards a reparative Mox phenotype.

Arsenite causes proteotoxicity by targeting nascent proteins for misfolding and aggregation. Here, we assessed how selected yeast chaperones and ubiquitin ligases contribute to proteostasis during arsenite stress. Loss of the ribosome‐associated chaperones Zuo1, Ssz1, and Ssb1/Ssb2 reduced global translation and protein aggregation, and increased arsenite resistance. Loss of cytosolic GimC/prefoldin function led to defective aggregate clearance and arsenite sensitivity. Arsenite did not induce ribosomal stalling or impair ribosome quality control, and ribosome‐associated ubiquitin ligases contributed little to proteostasis. Instead, the cytosolic ubiquitin ligase Rsp5 was important for aggregate clearance and resistance. Our study suggests that damage prevention, by decreased aggregate formation, and damage elimination, by enhanced aggregate clearance, are important protective mechanisms that maintain proteostasis during arsenite stress.

Exposure to toxic metals and metalloids such as cadmium and arsenic results in widespread misfolding and aggregation of cellular proteins. How these protein aggregates are formed in vivo, the mechanisms by which they affect cells, and how cells prevent their accumulation during environmental stress is not fully understood. To find components involved in these processes, we performed a genome-wide imaging screen and identified yeast deletion mutants with either enhanced or reduced protein aggregation levels during arsenite exposure. Mutants with reduced aggregation levels were enriched for functions related to protein biosynthesis and transcription, whilst functions related to cellular signalling, metabolism, and protein folding and degradation were overrepresented among mutants with enhanced aggregation levels. On a genome-wide scale, protein aggregation correlated with arsenite resistance and sensitivity, indicating that many of the identified factors are crucial to safeguard protein homeostasis (proteostasis) and to protect against arsenite toxicity. Dedicated follow-up experiments indicated that intracellular arsenic is a direct cause of protein aggregation and that accurate transcriptional and translational control are crucial for proteostasis during arsenite stress. Specifically, we provide evidence that global transcription affects protein aggregation levels, that loss of transcriptional control impacts proteostasis through distinct mechanisms, and that translational repression is central to control protein aggregation and cell viability. Some of the identified factors are associated with pathological conditions suggesting that arsenite-induced protein aggregation may impact disease processes. The broad network of cellular systems that impinge on proteostasis during arsenic stress provides a valuable resource and a framework for further elucidation of the mechanistic details of metalloid toxicity and pathogenesis.AUTHOR SUMMARYHuman exposure to poisonous metals is increasing in many parts of the world and chronic exposure is associated with certain protein folding-associated disorders such as Alzheimer’s disease and Parkinson’s disease. While the toxicity of many metals is undisputed, their molecular modes of action have remained unclear. Recent studies revealed that toxic metals such as arsenic and cadmium profoundly affect the correct folding of proteins, resulting in the accumulation of toxic protein aggregates. In this study, we used high-content microscopy to identify a broad network of cellular systems that impinge on protein homeostasis and cell viability during arsenite stress. Follow-up experiments highlight the importance of accurate transcriptional and translational control for mitigating arsenite-induced protein aggregation and toxicity. Some of the identified factors are associated with pathological conditions suggesting that arsenite-induced protein aggregation may impact disease processes. The broad network of cellular systems that impinge on proteostasis during arsenic stress provides a valuable resource and a framework for further elucidation of the mechanistic details of metal toxicity and pathogenesis.

Inflammation plays a central role in ischemic stroke. During brain inflammation the resident macrophages of the brain, the microglia cells, are rapidly activated. In the periphery, α7 nicotinic acetylcholine receptors (α7R) present on macrophages can regulate inflammation by suppressing cytokine release. In the current study we investigated the expression α7R in mice after middle cerebral artery occlusion (MCAO). We further examined possible anti‐inflammatory role of α7R stimulation in vitro and microglia polarization after α7R agonist treatment. Real‐time PCR analysis showed a 58% reduction in α7R expression 72 h post MCAO. Stimulation of primary microglial cells with LPS in combination with increasing doses of the selective α7R agonist AR‐R 17779 significantly attenuated TNF‐α release and increased α7R transcript in microglial cells. Gene expression of M1 markers CD86 and iNOS, as well as M2 markers CD206 and Arginase1 was not influenced by LPS and/or α7R agonist treatment, however, Mox markers heme oxygenase (Hmox1) and sulforedoxin‐1 (Srx1) were significantly increased, suggesting a polarization towards the Mox phenotype after α7R stimulation. Thus, our data support the anti‐inflammatory role of α7R in the brain after MCAO and in microglia, suggesting that α7R stimulation could enhance the polarization towards a reparative Mox phenotype.

Arsenic is a toxic metalloid that affects human health by causing numerous diseases and by being used in the treatment of acute promyelocytic leukemia. Saccharomyces cerevisiae (budding yeast) has been extensively utilized to elucidate the molecular mechanisms underlying arsenic toxicity and resistance in eukaryotes. In this study, we applied a genomic DNA overexpression strategy to identify yeast genes that provide arsenic resistance in wild‐type and arsenic‐sensitive S. cerevisiae cells. In addition to known arsenic‐related genes, our genetic screen revealed novel genes, including PHO86, VBA3, UGP1 , and TUL1 , whose overexpression conferred resistance. To gain insights into possible resistance mechanisms, we addressed the contribution of these genes to cell growth, intracellular arsenic, and protein aggregation during arsenate exposure. Overexpression of PHO86 resulted in higher cellular arsenic levels but no additional effect on protein aggregation, indicating that these cells efficiently protect their intracellular environment. VBA3 overexpression caused resistance despite higher intracellular arsenic and protein aggregation levels. Overexpression of UGP1 led to lower intracellular arsenic and protein aggregation levels while TUL1 overexpression had no impact on intracellular arsenic or protein aggregation levels. Thus, the identified genes appear to confer arsenic resistance through distinct mechanisms but the molecular details remain to be elucidated.